DUX4 and facioscapulohumeral muscular dystrophy: In fact, much preclinical and clinical endeavor is directed at suppressing ongoing DUX4 expression as a therapy, although DUX4 mRNA/protein are notoriously difficult to detect in both FSHD patient-derived muscle cells and post-natal muscle biopsies.